The Nuclear Domains and Pathologies Team studies the emerging role of ribosomes in cancer development. We identify cancer specific alterations of the ribosomes and of the ribosome production machinery with two aims: first to better understand the process of tumor development and second to apply this knowledge to the development of novel therapeutic and diagnostic strategies for cancer. We concentrate on models of breast and colon cancer development and response to chemotherapies.